Swedish StromaBio AB
Swedish StromaBio is a clinical stage biopharma company building on more than two decades of research on mesenchymal stromal cells (MSC).
Swedish StromaBio was founded in 2018 with the aim to develop registered products based on mesenchymal stromal cells (MSC).
Historically, cell therapy has been used for transplantations and for hospitals to set up in their own regime. Since the clinical demand and potential applications for MSCs increased use of MSCs became defined as an advanced therapy medicinal product (ATMP). This regulation prevents from treatments without a registered product on most of the markets but increases the possibility to reach substantial income from products registered for different indications. The key is a deep knowledge in the MSCs together with how they affect targeted indications.
StromaBio aims to take the development of MSCs to market through clinical trials with the goal to generate products for several indications. StromaBio’s MSC product, “StromaForte” is already used in two clinical trials.
StromaBio is a subsidiary to Takura AB: www.takura.se
StromaBio is founded on a strong scientific platform of cell biology, immunology and transplantation biology. With this knowledge we aim to target conditions with a strong inflammatory component. The MSC will modulate the inflammation and induce a healthy regeneration.